Bio Loomics Appoints Kurt Gish, Ph.D., As Chief Scientific Officer
06/13/24, 7:22 PM
Location
boulderIndustry
information technology
Position
chief scientific officer
BioLoomics, a biotechnology company targeting peptide-antibody chimeras to specific compartments inside of diseased cells, has announced the appointment of Kurt Gish, Ph.D., as the Chief Scientific Officer. Dr. Gish will focus on building the company’s pipeline of lysosomal targeting ADCs in oncology to overcome the limitations of poor tumor uptake, which hinders safety and efficacy across the ADC market.
Company Info
Location
4665 nautilus ct. s.
boulder, colorado, united states
Additional Info
Headquartered in Colorado, BioLoomics is a preclinical stage biotechnology company pioneering directed evolution of antibody-peptide chimeras with programmable internalization and lysosome targeting. Lysosome targeted antibody-peptide chimeras have broad utility to elicit increased payload delivery mechanisms in the ADC therapeutic space. The company has raised a total of $10.1 million from top investors including Innovations Endeavors, Horizons Ventures, TechU Ventures, Boom Capital Ventures, BoxOne Ventures, GC&H, and Viswa Colluru.